Among 40 recurrent driver alterations described in breast cancer, only HER2 amplification, germline BRCA1/2 mutations, and PIK3CA mutations were given level 1A evidence as molecular targets whereas NTRK fusions and microsatellite instability (MSI) were ranked as 1C evidence. This evidence concerns the gene BRCA1 and breast carcinoma.